Using biomarkers to predict treatment response in major depressive disorder: Evidence from past and present studies

Dialogues in Clinical Neuroscience

Volumn 16, Issue 4, 2014, Pages 539-544

  Thase, Michael E ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Antidepressant; Biomarker; Cognitive behavior therapy; Prediction; Treatment response

Indexed keywords

ACETYLCHOLINE; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; ESCITALOPRAM; HYDROCORTISONE; INFLIXIMAB; MONOAMINE; NEUROTRANSMITTER; NORTRIPTYLINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL PRACTICE; COGNITIVE THERAPY; DEXAMETHASONE SUPPRESSION TEST; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAM; EMOTION; EVOKED CORTICAL RESPONSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE ACTIVITY; GLUCOSE METABOLISM; HIGH RISK POPULATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPERCORTISOLISM; INFLAMMATION; MAJOR DEPRESSION; NONHUMAN; OUTPATIENT CARE; PATHOPHYSIOLOGY; POLYSOMNOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PSYCHOTHERAPY; REM SLEEP; SLEEP DISORDER; TRANSCRIPTOMICS; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; WEIGHT REDUCTION; DEPRESSIVE DISORDER, MAJOR; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; BIOMARKERS; COGNITIVE THERAPY; DEPRESSIVE DISORDER, MAJOR; HUMANS; TREATMENT OUTCOME;

EID: 84925296177     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kessler RC, Merikangas KR, Wang PS. Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Ann Rev Clin Psychol. 2007;3:137-158.
2. Insel TR, Wang PS. The STAR*D trial: revealing the need for better treatments. Psychiatr Serv. 2009;60:1466-1467.
3. Smith DF. Quest for biomarkers of treatment-resistant depression: shifting the paradigm toward risk. Front Psychiatry. 2013;4:57.
4. Thase ME, Howland R. Biological processes in depression: updated review and integration. In: Beckham EE, Leber WR, eds. Handbook of Depression. New York, NY: Guilford Press; 1995;213-279.
5. Ribeiro SC, Tandon R, Grunhaus L, Greden JF. The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry. 1993;150:1618-1629.
6. Owens M, Herbert J, Jones PB, et al. Elevated morning cortisol is a stratified population-level biomarker for major depression in boys only with high depressive symptoms. Proc Natl Acad Sci U S A. 2014;111:3638-3643.
7. Thase ME, Dubé S, Bowler K, Howland RH, Myers JE, Friedman E, Jarrett DB. Hypothalamic-pituitary-adrenocortical activity and response to cognitive behavior therapy in unmedicated, hospitalized depressed patients. Am J Psychiatry. 1996;153:886-891.
8. Thase ME, Kupfer DJ. Current status of EEG sleep in the assessment and treatment of depression. In: Burrows GD, Werry JW, eds. Advances in Human Psychopharmacology. Volume 4. Greenwich, CT: JAI Press, Inc; 1987;93-148.
9. Benca RM, Obermeyer WH, Thisted RA, Gillin JC. Sleep and psychiatric disorders. A meta-analysis. Arch Gen Psychiatry. 1992;49:651-668.
10. Thase ME, Buysse DJ, Frank E, et al. Which depressed patients will respond to interpersonal psychotherapy? The role of abnormal EEG sleep profiles. Am J Psychiatry. 1997;154:502-509.
11. Thase ME, Simons AD, Reynolds CF 3rd. Abnormal electroencephalographic sleep profiles in major depression: association with response to cognitive behavior therapy. Arch Gen Psychiatry. 1996;53:99-108.
12. Thase ME, Kupfer DJ, Fasiczka AJ, Buysse DJ, Simons AD, Frank E. Identifying an abnormal electroencephalographic sleep profile to characterize major depressive disorder. Biol Psychiatry. 1997;41:964-973.
13. Thase ME, Fasiczka AL, Berman SR, Simons AD, Reynolds CF 3rd. Electroencephalographic sleep profiles before and after cognitive behavior therapy of depression. Arch Gen Psychiatry. 1998;55:138-144.
14. Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety. 2013;30:297-306.
15. Carvalho LA, Torre JP, Papadopoulos AS, et al. Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J Affect Disord. 2013;148:136-140.
16. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment- resistant depression: the role of baseline inflammatory biomarkers. JAMA. 2013;70:31-41.
17. Uher R, Tansey KE, Dew T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014. Epub ahead of print: doi: 10.1176/appi.ajp.2014.14010094.
18. Pajer K, Andrus BM, Gardner W, et al. Discovery of blood transcriptomic markers for depression in animal models and pilot validation in subjects with early-onset major depression. Transl Psychiatry. 2012. http://dx.doi.org/10.1038/tp.2012.26.
19. Redei EE, Andrus BM, Kwasny MJ, Seok J, Cai X, Ho J, Mohr DC. Blood transcriptomic biomarkers in adult primary care patients with major depressive disorder undergoing cognitive behavioral therapy. Transl Psychiatry. 2014; (http://dx.doi.org/10.1038/tp.2014.66).
20. Holtzheimer PE, Mayberg HS. Stuck in a rut: rethinking depression and its treatment. Trends Neurosci. 2011;34:1-9.
21. Kennedy SH, Konarski JZ, Segal ZV, et al. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry. 2007;164:778-788.
22. Fales CL, Barch DM, Rundle MM, et al. Antidepressant treatment normalizes hypoactivity in dorsolateral prefrontal cortex during emotional interference processing in major depression. J Affect Disord. 2009;112:206-211.
23. Downar J, Geraci J, Salomons TV, et al. Anhedonia and reward-circuit connectivity distinguish nonresponders from responders to dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression. Biol Psychiatry. 2014;76:176-185.
24. Harmer CJ, Cowen PJ, Goodwin GM. Efficacy markers in depression. Psychopharmacol. 2011;25:1148-1158.
25. Siegle GJ, Carter CS, Thase ME. Use of FMRI to predict recovery from unipolar depression with cognitive behavior therapy. Am J Psychiatry. 2006;163:735-738.
26. Siegle GJ, Thompson WK, Collier A, et al. Toward clinically useful neuroimaging in depression treatment: prognostic utility of subgenual cingulate activity for determining depression outcome in cognitive therapy across studies, scanners, and patient characteristics. Arch Gen Psychiatry. 2012;69:913-924.
27. Siegle GJ, Steinhauer SR, Friedman ES, Thompson WS, Thase ME. Remission prognosis for cognitive therapy for recurrent depression using the pupil: utility and neural correlates. Biol Psychiatry. 2011;69:726-733.
28. McGrath CL, Kelley ME, Holtzheimer PE, Dunlop BW, Craighead WE, Franco AR, Craddock RC, Mayberg HS. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA. 2013;70:821-829.
29. Trivedi MH, McGrath P, Fava M, et al. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): rationale and design. J Psych Res. In press.
30. GENDEP Investigators, MARS Investigators, STAR*D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry. 2013;170:207-217.
31. Lobello KW, Preskorn SH, Guico-Pabia CJ, et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry. 2010;71:1482-1487.
32. Papakostas GI, Shelton RC, Zajecka JM, et al. Effect of adjunctive Lmethylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry. 2014;75:855-863.